Everything below concerns deamidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
=== CBRN equipment === Light Anti-Gas Respirator - Issued until the arrival of the S6 respirator. S6 NBC Respirator - Issued from 1966 S10 NBC Respirator - Issued from 1986 No. 1 Mk 1-4 Protective Suit
==== Member of the Royal Victorian Order (MVO) ==== Christian Mary Bailey, Curator to The Prince of Wales. Frederick Booth, Chief Heraldic Painter, College of Arms. Ann Teresa Brown, , lately British Overseas Trade Board. Matthew Nicholas Butler, lately Assistant Private Secretary to The Prince of Wales Pamela Margaret Clark, Deputy Registrar, Royal Archives, Windsor Castle. Claire Elizabeth Hunter-Craig, Secretary, Household of The Duke of Edinburgh. Reginald Elliott, Higher Executive Officer, Crown Estate, Windsor. Valerie Winifred Hampton, Personal Secretary to Princess Alexandra, the Honourable Lady Ogilvy. Chief Yeoman Warder Norman William Jackson, HM Tower of London. Alexander Masson, Head Gamekeeper, Balmoral Estate. John Ronald Pepper, lately of Collingwood & Company Limited. Inspector Stephen Lionel Robinson, Royalty and Diplomatic Protection Department, Metropolitan Police. Eileen Margaret Sly, lately the Westminster Abbey Trust. William Albert Stewart, Head Warden, Palace of Holyroodhouse. Prudence Sarah Sutcliffe, Assistant Curator of the Print Room, Windsor Castle. Lieutenant Colonel Patrick John Tabor, lately Equerry to The Prince of Wales.
== Causes == The Jarisch–Herxheimer reaction is traditionally associated with antimicrobial treatment of syphilis. The reaction is also seen in the other diseases caused by spirochetes: Lyme disease, relapsing fever, and leptospirosis. There have been case reports of the Jarisch–Herxheimer reaction accompanying treatment of other infections, including Q fever, bartonellosis, brucellosis, trichinellosis, and African trypanosomiasis.
April 9: Decree setting the structure, staffing, status, and pay for laboratory personnel (under the Ministry of Public Health): women may be assistants but may not hold leadership positions, nor the roles of head technician or "lab boy." October 30: Decree on child protection. October 30: Decree amending Articles 376 and following of the Civil Code; modifies the "right of parental discipline" — for both father and mother — and the terms and duration of placing a child under care. 1936
Sources: en.wikipedia.org
uridine monophosphate (UMP)), usually to tyrosine propionylation pyroglutamate formation S-glutathionylation S-nitrosylation S-sulfenylation, reversible covalent addition of one oxygen atom to the thiol group of a cysteine residue to form a sulfenic acid S-sulfinylation, normally irreversible covalent addition of two oxygen atoms to the thiol group of a cysteine residue to form a sulfinic acid S-sulfonylation, normally irreversible covalent addition of three oxygen atoms to the thiol group of a cysteine residue, resulting in the formation of a cysteic acid residue sulfation, the addition of a sulfate group to a tyrosine.
Originally, René Just Haüy considered that each chemical compound had a characteristic crystalline form. However, based on his 1808 work with aragonite and his earlier studies of calcite, which are two different forms of calcium carbonate (CaCO3), Haüy had to concede that substances with the same chemical composition but different molecular arrangements could have different crystalline forms. In 1819 Eilhard Mitscherlich discovered the law of isomorphism which states that compounds which contain the same number of atoms, and have similar structures, tend to exhibit similar crystal forms. Mitscherlich carried out the first systematic research on the dependence of crystal forms on their chemical nature. The discovery of isomorphism was the first major step in chemical crystallography and Emil Wohlwill regarded Mitscherlich's work on isomorphism as a milestone in the history of the atomic-molecular theory. The discovery of the phenomena of isomorphism and polymorphism dealt a clear blow to Haüy's crystal structure theory. Mitscherlich's findings were a central consideration of the atomic weight determinations in 1819 by Jöns Jacob Berzelius, a leading proponent of Dalton's atomic theory. Berzelius classified minerals by their chemical composition rather than by their crystal morphology, as was the established practice. Mitscherlich's research, together with the work of Alexis Thérèse Petit and Pierre-Louis Dulong that heat capacities of solids vary with temperature and inversely with atomic weight, led Berzelius to declare them as a positive confirmation of the atomic theory.
=== 26 February === According to a Russian source, border clashes between Belarus and Ukraine resulted in the death of one Belarusian soldier. A Russian Beriev A-50U plane at the Machulishchy air base was said to have been destroyed by Belarusian partisans. However, satellite imagery of the Machulishchy air base from 28 February showed the sole A-50 located there still largely intact.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.